Fortis Therapeutics

    OverviewSuggest Edit

    Fortis Therapeutics is a company developing immuno-oncology biotechnology. It focuses on developing new antibody-drug conjugate therapies against CD46 for the treatment of late-stage multiple myeloma and late-stage prostate cancer and other indications. To create its product called FOR46, the fully human antibody was conjugated to a potent payload using a chemistry platform with Vivo properties. In vitro studies of FOR46 have demonstrated its potential to kill tumor cells with no effect on normal cells.
    TypePrivate
    Websitefortistx.com

    Latest Updates

    Cybersecurity ratingAMore
    Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
    Banner background

    Key People/Management at Fortis Therapeutics

    Jay Lichter

    Jay Lichter

    Director & Chief Executive Officer
    Marc Nasoff

    Marc Nasoff

    Chief Science Officer
    Leonard Post

    Leonard Post

    Chief Development Office
    Andy Dorr

    Andy Dorr

    Chief Medical Officer
    Tighe Reardon

    Tighe Reardon

    CFO
    Show more

    Fortis Therapeutics Online and Social Media Presence

    Embed Graph

    Fortis Therapeutics Frequently Asked Questions

    • Who are Fortis Therapeutics key executives?

      Fortis Therapeutics's key executives are Jay Lichter, Marc Nasoff and Leonard Post.

    • Who are Fortis Therapeutics competitors?

      Competitors of Fortis Therapeutics include CytoTrack, AI4R and Syndivia.